Macroaxis: Personalized Investing  
Macroaxis Country Selector USA  Change      Macroaxis User Registration Register    Macroaxis User Login Sign In
   
 US Market Closed: Feb 9, 20:05 PM 2012 
  NYSE  8081.25  1.73  Index Moved Down   NASDAQ  2927.23  11.37  Index Moved Up 
 and more..
Search
sponsered by
  
  



Processing
Collecting necessary data for ACUR...
       

Acura financials and fundamentals

       
  Companies   Sectors   Advisers
       
    
       
3.24
  
Acura Quote
Intraday
 
Acura Intraday Quote
One Month
 0.01   Macroaxis: 0.31 Up   0.31%  
 2.28 Year To Date 6.8 
 3.2 Trading Day  3.31 
Embed Now
    
Diversification Suggestion
Use Acura to enhance returns of your portfolios. The stock experiences normal upward fluctuation
1 Month Beta vs NYSE ......... 2.23
As NYSE goes up, Acura is expected to significantly outperform it. However, if the market returns are negative, Acura will likely underperform.
Acura Large Beta
    
ACUR Macroaxis: United States NCMAcura Quote: Bull
Acura Pharmaceuticals Inc.
http://www.acurapharm.com
847-705-7709
Trade Acura
Run Report
 Run Report 
Correlation
 Correlation 
Drug Delivery  
Market Capitalization 146.8M  
Earnings Per Share 0.191  
Today Lowest 3.20  
Book Value Per Share 0.838  
Robert B. Jones executive  Robert B. Jones
Chief officer, Pres and Director 
Peter A. Clemens executive  Peter A. Clemens
Chief Financial Officer, Principal  
Robert A. Seiser executive  Robert A. Seiser
VP, Treasurer and Corp. Controller 
Dr. Albert W. Brzeczko Ph.D. executive Dr. Albert W. Brzeczko Ph.D.
VP of Technical Affairs 
James F. Emigh R.PH. executive  James F. Emigh R.PH.
VP of Corp. Devel. 

Acura fundamentals

    
P/E16.91Open3.26
P/B Ratio3.85Volume65479
SectorHealthcareLast Close3.23
Short Ratio27.30Last Traded2/9/2012
Year High6.80Percent ChangePrice Moved Up 0.31%
Year Low2.28Absolute Change0.01 Price Moved Up
EPS0.191Index MembershipNot Applicable
Day High3.31Day Low3.20
Target Price8.00Current EPS0.191
Current PE16.91This Year PENot Applicable
    

Acura Performance    Embed Financials for Acura Pharmaceuticals Inc.

    
    
 Embed Financials for Acura Pharmaceuticals Inc.

Acura Profile

    
Acura Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the research, development, and manufacture of pharmaceutical product candidates utilizing its proprietary Aversion and Impede technologies.
 Macroaxis: United States IXIC   0.39 % Macroaxis: 0.39 Moved Up  
 
 Macroaxis: thisGreen ACUR   0.31 % Macroaxis: 0.31 Moved Up  
 
 Macroaxis: United States GSPC   0.15 % Macroaxis: 0.15 Moved Up  
 
 Macroaxis: United States NYA   0.02 % Macroaxis: 0.02 Moved Down  
 
 Live Sentiment  
 Bulls VITSX 
 NASDAQ Macroaxis: United States 
 Bought over 300 shares of
 48 minutes ago
for 34.0 
 Bulls VWILX 
 NASDAQ Macroaxis: United States 
 Bought over 100 shares of
 49 minutes ago
for 58.49 
 Bulls VEXRX 
 NASDAQ Macroaxis: United States 
 Bought over 100 shares of
 49 minutes ago
for 74.5 
 Bulls LPHI 
 NASDAQ Macroaxis: United States 
 Bought over 400 shares of
 One hour ago
for 4.87 
 Bulls ROAC 
 NGM Macroaxis: United States 
 Bought over 300 shares of
 One hour ago
for 5.24 
    

Acura 30-Days Moving Rating

    

Macroaxis Total Score 

    
0
Embed Financials
Current 30 Days Moving Rating
    
    

Estimated Market Risk

 4.74
  actual daily
 
 20 %
of total potential
 
Market Risk score

Expected Return

 -0.32
  actual daily
 
 1 %
of total potential
 
Expected Return score

Risk-Adjusted Return

 -0.07
  actual daily
 
 1 %
of total potential
 
Risk-Adjusted Return score
Based on monthly moving average   [ change ] 
Increase Risk-Adjusted return of ACUR by adding it to a well-diversified portfolio
Diversify
    

 Acura Last Intraday

    
 
0.01Macroaxis: 0.01 Down0.31%
 
3.23,3.23,3.24,3.24,3.20,3.31,3.24
 
3.233.24
    

Latest headlines for Acura


Few days ago at www.benzinga.com      Got to news item   

Will Acura Pharmaceuticals Bring Relief to Investors?

By Matthew Kennedy Acura Pharmaceuticals (NASDAQ: ACUR) is a small pharmaceutical company that develops pain relief drugs. Its flagship medication is OXECTA, a pain relief drug developed in ...
Few days ago at www.marketwatch.com      Got to news item   

Kahn Swick & Foti, LLC Announces Class Action Settlement on Behalf of Purchasers of Publicly-Traded Securi...

CHICAGO, Nov. 28, 2011 /PRNewswire via COMTEX/ -- Kahn Swick & Foti, LLC announces that the United States District Court Northern District of Illinois Eastern Division approved the following ... Kahn Swick & Foti, LLC Announces Class Action Settlement on Behalf of Purchasers of Publicly-Traded Securities of Acura Pharmaceuticals, Inc. -- ACUR - DigitalJournal.com
Few days ago at www.marketwatch.com      Got to news item   

Kahn Swick & Foti, LLC Announces Class Action Settlement on Behalf of Purchasers of Publicly-Traded Securi...

CHICAGO, Nov. 28, 2011 /PRNewswire via COMTEX/ -- Kahn Swick & Foti, LLC announces that the United States District Court Northern District of Illinois Eastern Division approved the following ... Kahn Swick & Foti, LLC Announces Class Action Settlement on Behalf of Purchasers of Publicly-Traded Securities of Acura Pharmaceuticals, Inc. -- ACUR - DigitalJournal.com
Few days ago at stocks.us.reuters.com      Got to news item   

Kahn Swick & Foti, LLC Announces Class Action Settlement On Behalf Of Purchasers Of Publicly-Traded Securi...

Reuters Key Development - Nov 28, 2011
Few days ago at www.twst.com      Got to news item   

The Wall Street Transcript Exclusive Interview With The President And CEO: Acura Pharmaceuticals, Inc. (ACUR) ...

The Wall Street Transcript is a completely unique resource for investors and business researchers. Thousands of in-depth interviews with CEOs, Industry Analysts and Professional Money Managers ...


 

 
Analytics
Investor Landscape
Efficient Frontier
Market Correlation
Risk and Return Analysis
Financial Content New financial content
Portfolio Projections
Retirement Optimizer
RSS and Mobile Access
Market
FAQs
Stock Screener
Fund Screener
ETF Screener
Company Directory
Advisor Directory
Technology
Wealth Management
About Us
About Macroaxis
Contact Us
Terms Of Use
Privacy Policy
Site Map
Product Tour
Investment Services
More ROI More Return on Investment
© 2011 Macroaxis Inc. All rights reserved